Outcome Reporting Among Drug Trials Registered in ClinicalTrials.gov
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Clinical trial registries are in widespread use to promote transparency around trials and their results. OBJECTIVE: To describe characteristics of drug trials listed in ClinicalTrials.gov and examine whether the funding source of these trials is associated with favorable published outcomes. DESIGN: An observational study of safety and efficacy trials for anticholesteremics, antidepressants, antipsychotics, proton-pump inhibitors, and vasodilators conducted between 2000 and 2006. SETTING: ClinicalTrials.gov, a Web-based registry of clinical trials launched in 1999. MEASUREMENTS: Publications resulting from the trials for the 5 drug categories of interest were identified, and data were abstracted on the trial record and publication, including timing of registration, elements of the study design, funding source, publication date, and study outcomes. Assessments were based on the primary funding categories of industry, government agencies, and nonprofit or nonfederal organizations. RESULTS: Among 546 drug trials, 346 (63%) were primarily funded by industry, 74 (14%) by government sources, and 126 (23%) by nonprofit or nonfederal organizations. Trials funded by industry were more likely to be phase 3 or 4 trials (88.7%; P < 0.001 across groups), to use an active comparator in controlled trials (36.8%; P = 0.010 across groups), to be multicenter (89.0%; P < 0.001 across groups), and to enroll more participants (median sample size, 306 participants; P < 0.001 across groups). Overall, 362 (66.3%) trials had published results. Industry-funded trials reported positive outcomes in 85.4% of publications, compared with 50.0% for government-funded trials and 71.9% for nonprofit or nonfederal organization-funded trials (P < 0.001). Trials funded by nonprofit or nonfederal sources with industry contributions were also more likely to report positive outcomes than those without industry funding (85.0% vs. 61.2%; P = 0.013). Rates of trial publication within 24 months of study completion ranged from 32.4% among industry-funded trials to 56.2% among nonprofit or nonfederal organization-funded trials without industry contributions (P = 0.005 across groups). LIMITATIONS: The publication status of a trial could not always be confirmed, which could result in misclassification. Additional information on study protocols and comprehensive trial results were not available to further explore underlying factors for the association between funding source and outcome reporting. CONCLUSION: In this sample of registered drug trials, those funded by industry were less likely to be published within 2 years of study completion and were more likely to report positive outcomes than were trials funded by other sources. PRIMARY FUNDING SOURCE: National Library of Medicine and National Institute of Child Health and Human Development, National Institutes of Health.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The manner in which these processes are used vary from study to study and are known to be time-consuming.9 26 27”
From Systematic review protocol assessing the processes for linking clinical trial registries and their published results (2016) · cites this paper as [9]
In the citing paper
“The manner in which these processes are used vary from study to study and are known to be time-consuming.9 26 27”
From Systematic review protocol assessing the processes for linking clinical trial registries and their published results (2016) · cites this paper as [9]
In the citing paper
“Clinical trial registries are an important source of information for tracking clinical trials from their inception through to their reporting, and have been used to measure publication bias and outcome reporting bias.”
From Systematic review protocol assessing the processes for linking clinical trial registries and their published results (2016) · cites this paper as [9]
Citations
Cites
Why Most Published Research Findings Are False
Ioannidis, J. P. A. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020124 · Cited by 10,505
Why Most Published Research Findings Are False
Ioannidis, J. P. A. (2005) · CHANCE · doi:10.1080/09332480.2005.10722754 · Cited by 4,702 · cited 1×
“Biased publication and reporting of results compromises the integrity of the medical literature by providing an incomplete account of the evidence (2, 7, 8).”
Selective publication of antidepressant trials and its influence on apparent efficacy
Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., & Rosenthal, R. (2008) · New England Journal of Medicine · doi:10.1056/nejmsa065779 · Cited by 2,435 · cited 1×
“Food and Drug Administration (FDA) remain unpublished 5 years after drug approval, and examination of unpublished results reveals striking discrepancies between existing trial results and results available in the published literature (10, 13).”
Pharmaceutical industry sponsorship and research outcome and quality: systematic review
Lexchin, J., Bero, L. A., Djulbegovic, B., & Clark, O. (2003) · BMJ · doi:10.1136/bmj.326.7400.1167 · Cited by 2,147 · cited 1×
“Systematic reviews of the literature have shown that industryfunded trials are more than 4 times more likely to report findings supporting their product than are trials without financial interests (34).”
Chan, A.-W., Hróbjartsson, A., Haahr, M. T., Gøtzsche, P. C., & Altman, D. G. (2004) · JAMA · doi:10.1001/jama.291.20.2457 · Cited by 1,845 · cited 1×
“Without impartial, a priori registration of trials, planned data analyses and study outcomes may be altered or omitted in favor of the experimental treatment after trial data are available (33, 43, 44).”
Scope and Impact of Financial Conflicts of Interest in Biomedical Research: A Systematic Review
Bekelman, J. E., Li, Y., & Gross, C. P. (2003) · JAMA · doi:10.1001/jama.289.4.454 · Cited by 1,816
Clinical Trial Registration: A Statement from the International Committee of Medical Journal Editors
De Angelis, C., Drazen, J. M., Frizelle, F. A., Haug, C., Hoey, J., Horton, R., Kotzin, S., Laine, C., Marusic, A., Overbeke, A. J. P. M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejme048225 · Cited by 1,241
Publication bias: the case for an international registry of clinical trials.
Simes, R. J. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.10.1529 · Cited by 747 · cited 1×
“Biased publication and reporting of results compromises the integrity of the medical literature by providing an incomplete account of the evidence (2, 7, 8).”
Als-Nielsen, B., Chen, W., Gluud, C., & Kjaergard, L. L. (2003) · JAMA · doi:10.1001/jama.290.7.921 · Cited by 746 · cited 1×
“Unknown or incomplete information about trial details makes factors that influence trial outcomes difficult to account for and measure (26, 32, 40).”
Comparison of Registered and Published Primary Outcomes in Randomized Controlled Trials
Mathieu, S. (2009) · JAMA · doi:10.1001/jama.2009.1242 · Cited by 730 · cited 4×
“This finding is not surprising, considering that a recent study found that 37% of journals did not provide guidelines on registration requirements in instructions to authors and 27% of published trials were not registered (5).”
Influential
Research works printed but not linked: 1
- Bhandari M, 2004, CMAJ, 170, 477
Cited by
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
Chan, A.-W., Tetzlaff, J. M., Gotzsche, P. C., Altman, D. G., Mann, H., Berlin, J. A., Dickersin, K., Hrobjartsson, A., Schulz, K. F., Parulekar, W. R., et al. (2013) · BMJ · doi:10.1136/bmj.e7586 · Cited by 6,251
Industry sponsorship and research outcome
Lundh, A., Lexchin, J., Mintzes, B., Schroll, J. B., & Bero, L. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000033.pub3 · Cited by 1,697
Dwan, K., Gamble, C., Williamson, P. R., Kirkham, J. J., & the Reporting Bias Group (2013) · PLoS ONE · doi:10.1371/journal.pone.0066844 · Cited by 1,127
Billingham, S. A., Whitehead, A. L., & Julious, S. A. (2013) · BMC Medical Research Methodology · doi:10.1186/1471-2288-13-104 · Cited by 962
“[17], across a wide variety of types of trial, found that those funded by industry were more likely to have a larger sample size than those funded by government sources.”
BackgroundSodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes: A Systematic Review and Meta-analysis
Vasilakou, D., Karagiannis, T., Athanasiadou, E., Mainou, M., Liakos, A., Bekiari, E., Sarigianni, M., Matthews, D. R., & Tsapas, A. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-4-201308200-00007 · Cited by 911
“Incomplete reporting and inappropriate analysis plans are consistently criticized, and many organizations urge the need to rectify this problem (76).”
Metadata
- Authors
- Bourgeois, F. T., Murthy, S., & Mandl, K. D.
- Affiliations
- Boston Children's Hospital (US)
- Corresponding author
- Bourgeois, Florence T.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2010-08-03
- Volume
- 153
- Issue
- 3
- Pages
- 158-166
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- PMC
- PMC3374868
- OpenAlex
- W1967992635
- Cited by
- 332
- References
- 43
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 6 · 2023: 13 · 2022: 18 · 2021: 35 · 2020: 12 · 2019: 16 · 2018: 20 · 2017: 19 · 2016: 24 · 2015: 28 · 2014: 32 · 2013: 36 · 2012: 32
- FWCI
- 32.83
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Funders
- U.S. National Library of Medicine (G08LM009778)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (T32HD040128)
- Topics
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Meta-analysis and systematic reviews
- Keywords
- ClinicalTrials.gov, clinical trial registries, outcome reporting, publication bias, industry funding, trial funding, drug trials, antidepressants, antipsychotic drugs, proton pump inhibitors, vasodilators, clinical trial transparency, sample size, trial phase
- MeSH terms
- Clinical Trials as Topic, Drug Evaluation, Financing, Government, Financing, Organized, National Library of Medicine (U.S.), Periodicals as Topic, Registries, Research Support as Topic, United States, Publication Bias, Internet, Editorial Policies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Outcome Reporting Among Drug Trials Registered in ClinicalTrials.gov. https://app.cochat.ai/papers/10.7326/0003-4819-153-3-201008030-00006
- The paper
- Bourgeois, F. T., Murthy, S., & Mandl, K. D. (2010). Outcome Reporting Among Drug Trials Registered in ClinicalTrials.gov. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-153-3-201008030-00006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.